We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.23B
AUM Growth
+$5.22B
Cap. Flow
+$232M
Cap. Flow %
4.44%
Top 10 Hldgs %
34.65%
Holding
139
New
8
Increased
26
Reduced
20
Closed
24

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$97.9M
2
UNH icon
UnitedHealth
UNH
+$60M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$51.5M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$37.9M
5
THC icon
Tenet Healthcare
THC
+$26.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$94.8M
2
PFE icon
Pfizer
PFE
+$57.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$31M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$24.5M
5
VRNA
Verona Pharma
VRNA
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$340M 6.5%
2,718,735
– –
UNH icon
2
UnitedHealth
UNH
$389B
$202M 3.86%
380,500
+113,300
+42% +$60M
BMY icon
3
Bristol-Myers Squibb
BMY
$130B
$186M 3.56%
2,584,900
– –
BSX icon
4
Boston Scientific
BSX
$68.5B
$180M 3.45%
3,898,200
– –
HUM icon
5
Humana
HUM
$46.7B
$179M 3.42%
348,700
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$167M 3.2%
1,615,210
-102,100
-6% -$9.58M
ISRG icon
7
Intuitive Surgical
ISRG
$130B
$165M 3.15%
620,500
+47,800
+8% +$11.7M
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$137M 2.61%
5,250,000
-275,926
-5% -$6.8M
EWTX icon
9
Edgewise Therapeutics
EWTX
$4.34B
$130M 2.49%
14,567,176
– –
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.63B
$126M 2.41%
972,300
+53,800
+6% +$6.23M
VRNA
11
DELISTED
Verona Pharma
VRNA
$119M 2.29%
4,572,289
-1,122,552
-20% -$14.9M
SYK icon
12
Stryker
SYK
$133B
$118M 2.25%
481,000
+57,900
+14% +$13.1M
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$117M 2.25%
913,812
+151,212
+20% +$19.5M
CMPX icon
14
Compass Therapeutics
CMPX
$367M
$112M 2.15%
22,362,850
+402,000
+2% +$1.6M
TMO icon
15
Thermo Fisher Scientific
TMO
$214B
$111M 2.13%
202,200
– –
THRX
16
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$85.8M 1.64%
17,233,668
+192,000
+1% +$1.12M
NBIX icon
17
Neurocrine Biosciences
NBIX
$18.4B
$82.1M 1.57%
687,700
-208,845
-23% -$24.5M
KROS icon
18
Keros Therapeutics
KROS
$199M
$80.6M 1.54%
1,679,417
– –
EVH icon
19
Evolent Health
EVH
$421M
$79.3M 1.52%
2,824,832
+830,115
+42% +$23.8M
VRTX icon
20
Vertex Pharmaceuticals
VRTX
$124B
$78.4M 1.5%
271,500
-101,700
-27% -$31M
NTRA icon
21
Natera
NTRA
$36.1B
$78.2M 1.5%
1,946,353
+441,200
+29% +$18.2M
TERN
22
DELISTED
Terns Pharmaceuticals
TERN
$77.6M 1.48%
7,619,135
+137,931
+2% +$918K
IONS icon
23
Ionis Pharmaceuticals
IONS
$9.14B
$75.3M 1.44%
1,993,600
+1,224,700
+159% +$51.5M
SPRY icon
24
ARS Pharmaceuticals
SPRY
$563M
$74.6M 1.43%
8,740,887
– –
BIIB icon
25
Biogen
BIIB
$30.4B
$71.5M 1.37%
258,200
+33,600
+15% +$9.49M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2022 Portfolio in Review

As of Q4 2022, OrbiMed held 139 positions worth $5.23B, up 96,938% from $5.39M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed deployed $232M of net new capital in Q4 2022, opening 8 new positions and adding to 26 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 171,000 shares worth $19.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $94.8M trimmed.

  • OrbiMed's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 171,000 shares worth $19.5M.
  • OrbiMed added most to Disc Medicine in Q4 2022, an estimated $97.9M increase.
  • OrbiMed's biggest Q4 2022 reduction was argenx, cutting an estimated $94.8M.
  • OrbiMed fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $108K.
  • OrbiMed's ten largest holdings make up 35% of its $5.23B portfolio in Q4 2022.
  • OrbiMed opened 8 new positions and closed 24 in Q4 2022.
  • OrbiMed's portfolio value rose 96,938% quarter-over-quarter to $5.23B.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.